Navigation Links
FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
Date:11/6/2008

ia in a high risk acute coronary syndromes patient population.

The revised labeling includes new language noting that there was a significantly lower incidence of arrhythmias (ventricular tachycardia, bradycardia, supraventricular tachycardia and new atrial fibrillation) in patients treated with Ranexa versus placebo. This difference in arrhythmias did not lead to a reduction in mortality, a reduction in arrhythmia hospitalization or a reduction in arrhythmia symptoms.

The revised labeling also includes new language noting that Ranexa produces small reductions in HbA1c. Though Ranexa should not be considered a treatment for diabetes, Ranexa may be a particularly useful medication for the reduction of chronic angina in this patient population, which is difficult to treat because some anti anginal medications such as beta blockers increase HbA1c.

More than 150,000 patients have been prescribed Ranexa since its initial launch in March 2006.

Conference Call

Company management will webcast a conference call to discuss the FDA approval and third quarter 2008 financial results on Thursday, November 6 at 8:00 a.m. EST, 5:00 a.m. PST, on the Company's website. To access the live webcast, please log on to the Company's website at http://www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6241, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Thursday, November 13. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 68392680.

About Ranexa(R)

In the United Sates, Ranexa is indicated for the treatment o
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
2. FDA Approves Durameds LoSEASONIQUE(R) Oral Contraceptive
3. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
4. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
5. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
6. FDA Approves Fougeras Clotrimazole Cream USP 1%
7. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
8. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
9. Signalife Board Approves Merger
10. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
11. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... DIEGO , Feb. 27, 2015  Pfenex Inc. ... the development of biosimilar therapeutics, today announced that it ... Francisco Marriott Marquis on March 2 nd at ... participate on a panel discussing the current state of ... of Biosimilars . For more information ...
(Date:2/27/2015)... 27, 2015  Steep Hill, the industry leader in ... intends to open a full service medical cannabis quality ... , bringing advanced scientific tools and methodology to the ... Hill is currently the only laboratory licensed by the ... contaminant testing in order to meet the recently adopted ...
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript,s ... judgment notwithstanding the verdict, a new trial, and remittitur. ...
(Date:2/26/2015)... Synageva BioPharma Corp. (NASDAQ: GEVA ... rare disorders, today reported 2014 full year financial ... and financial guidance.  Synageva,s management team will host ... to review the financial results and provide a ... by telephone, please dial (877) 445-4603 for U.S. ...
Breaking Biology Technology:Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... 2011 ,   ... Matthew Roe as Chief Business Officer. Matthew joins,Crescendo ... Development & Licensing. During a 23-year ... management, acquisition, divestment, and sales,and marketing, and saw ...
... below 100 nanometres have numerous applications ranging from ... participates in a intragated FP7 European Project called ... nanoimprinting techniques (NIL), as a core aspect for ... followed are cost reduction, simpler fabrication process and ...
... classes of fundamental particles. Photons, the quanta of light, ... up atomic nuclei belong to the fermions. Bosons and ... level. This difference is expressed in their quantum statistics. ... was postulated, which was dubbed the anyon. In their ...
Cached Biology Technology:Crescendo Biologics Appoints Matthew Roe as Chief Business Officer 2Acrobatics for anyons: New test for elusive fundamental particle proposed 2
(Date:2/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD ... a new groundbreaking payment method. Payment accounts may be ... only be accessed if both the speech (the word ...
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/9/2015)... -- Lintec of America recently announced an exclusive license to ... including sheets, yarns and ribbons, developed at the University ... vast industrial resources of the global Lintec Group, headquartered ... America is forming the Nano-Science and Technology Center (NSTC) ... scaling up the manufacturing and commercialization of nano engineered ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... of getting from one place to another. Although many ... cues; things such as walls and corners to determine ... as rats and human children are so influenced by ... features such as a distinctive object or colored wall. ...
... with tendrils that extend far from the primary ... to an invariably poor prognosis. In a new ... journal PLoS Biology, Angela Johnston, Donna Senger, and ... mice with human gliomas and compared invasive cells ...
... Harvard University and the University of California, San Diego, ... genes determines the patterns of fur coloration that camouflage ... The work, published this week in the journal PLoS ... specific genetic changes have been linked to an organism,s ...
Cached Biology News:New study examines how rearing environment can alter navigation 2Interaction of just 2 genes governs coloration patterns in mice 2
... NAP-10 Columns, 50. For rapid and efficient ... in less than 15 minutes by gravity ... distilled water containing 0.15% Kathon CG/ICP Biocide.Available ... 0.5 ml (NAP-5), 1 ml (NAP-10) ...
Human ROR1 Affinity Purified Polyclonal Ab...
Human Rad1 MAb (Clone 33)...
Recombinant Ovine (Sheep) Growth Hormone, Ultra Pure...
Biology Products: